# Masatoshi Kudo

Source: https://onco.cc/people/masatoshi-kudo/  
OnCo record `masatoshi-kudo` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Japanese hepatologist who led REFLECT, the trial that made lenvatinib a first-line option for liver cancer.

## Summary

Masatoshi Kudo (Kindai University, Osaka) was principal investigator of REFLECT, which showed lenvatinib is non-inferior to sorafenib in unresectable hepatocellular carcinoma and became the first new first-line option in a decade. He has published extensively on combining systemic therapy with transarterial chemoembolisation and edits the journal Liver Cancer. He continues to lead HCC trials across Asia.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: hcc; japan; trialist
- Role: Professor and Chairman, Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine
- Specialisms: Hepatocellular carcinoma; Lenvatinib; Locoregional therapy; Hepatology

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Kudo%20M%5BAuthor%5D%20hepatocellular%20lenvatinib

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- institutions: [Kindai University Faculty of Medicine and Hospital](https://onco.cc/institutions/kindai-university-hospital/)
- trials: [REFLECT](https://onco.cc/trials/reflect/)

---
JSON: https://onco.cc/api/v1/entities/masatoshi-kudo.json